copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
A4 Basic Template - GSK GSK plc (LSE NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia Ojjaara is a once-a-day, oral JAK1 JAK2 and activin A receptor type 1
Press Release - GSK • GSK supports annual flu immunization by getting FLULAVAL and FLUARIX to patients in advance of flu season GSK plc (LSE NYSE: GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season This immediately follows a licensing and lot-release approval from the US Food and Drug
_______________________________________________________________________ Children 12 months and older: HAVRIX (Hepatitis A Vaccine) for those with a history of influenza vaccination; or HAVRIX (Dose 1) and a varicella vaccine (U S Licensed Manufactured by Merck Co , Inc or Non-U S Licensed Manufactured by GlaxoSmithKline Biologicals) (Dose 2) for those with no history of influenza vaccination
GSK Public policy positions April 2014 A publication of GlaxoSmithKline Communications and Government Affairs 2
US Version Blenrep ODAC Press Release_7. 17. 2025 FINAL FINAL GSK provides update on US FDA advisory committee review of Blenrep (belantamab mafodotin-blmf) combinations for patients with relapsed refractory multiple myeloma GSK plc (LSE NYSE: GSK) notes that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf
Stock-exchange announcement Tony Wood, Chief Scientific Officer, GSK, said: “We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by serogroup B Building on our global leadership in meningococcal vaccination and our longstanding commitment to address unmet need in disease prevention, we aim to help protect more teens and young
Stock-exchange announcement GSK plc (LSE NYSE: GSK) today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) as part of the adolescent meningococcal vaccination schedule Recommendations made by the ACIP are reviewed and, if adopted, are published as official
1. - us. gsk. com The requirements arise from both the Company’s equity listings and the debt listings of various subsidiaries, including GlaxoSmithKline Capital plc (GSK Capital) which has debt listed on the London Stock Exchange and the New York Stock Exchange